Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts.

OBJECTIVES Glucocorticoids effectively treat many diseases, but toxicity limits their utility. We aimed to learn whether, by reducing active intracellular glucocorticoid exposures, the 11β-hydroxysteroid dehydrogenase type 1 inhibitor clofutriben could selectively reduce glucocorticoid efficacy but reduce toxicity more strongly. We hypothesised that by increasing the prednisolone dose, it might be possible to restore efficacy back to the original level, thereby improving the benefit-risk profile. METHODS In sequential cohorts, adults with polymyalgia rheumatica received (single blind) prednisolone 10 mg/d with placebo for 2 weeks, then clofutriben with either prednisolone 10, 15, 20, or 30 mg/d for 2 weeks. RESULTS Forty-nine and 47 participants completed each trial period with evaluable data. Five who received prednisolone 10 mg/d with clofutriben experienced clinical relapse. No clinical relapses occurred during other treatments. Participants reported more severe symptoms and physical disability when prednisolone 10 mg/d or 15 mg/d, but not 20 mg/d or 30 mg/d, was given with clofutriben. Inflammatory biomarkers followed a similar pattern. Across all prednisolone doses, clofutriben coadministration mitigated glucocorticoid-related adverse effects on biomarkers of bone turnover, lipid metabolism, hypercoagulability, and cardiovascular and adrenal function. CONCLUSIONS Further trials to assess clofutriben's potential to improve the benefit-risk profile of prednisolone are warranted.

• Publication year

  2025

• Venue

  Annals of the Rheumatic Diseases

• Publication date

  2025-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.ard.2025.10.015PMID 41224552
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• OP0058 Effects of clofutriben, a selective 11ß-hydroxysteroid dehydrogenase type 1 inhibitor, on efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica

  2025cited by this paper
• European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and therapy of glucocorticoid-induced adrenal insufficiency.

  2024cited by this paper
• Impaired 11β-HSD1 Activity in a Male Patient With Cushing Disease Resulting in Lack of the Full Cushingoid Phenotype

  2024cited by this paper
• The 11β-hydroxysteroid dehydrogenase type 1 inhibitor SPI-62 prevents morbidity in a mouse model of Cushing’s syndrome

  2024cited by this paper
• 11β-HSD1 inhibition in men mitigates prednisolone-induced adverse effects in a proof-of-concept randomised double-blind placebo-controlled trial

  2023cited by this paper
• Continuing versus tapering low-dose glucocorticoids in patients with rheumatoid arthritis and systemic lupus erythematosus in states of low disease activity or remission: A systematic review and meta-analysis of randomised trials.

  2023cited by this paper
• Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults

  2023cited by this paper
• Safety and efficacy associated with long-term low dose glucocorticoids in rheumatoid arthritis: a systematic review and meta-analysis.

  2023cited by this paper
• An open-label phase Ⅰ/Ⅱ a clinical trial of 11β-HSD1 inhibitor for Cushing's syndrome and autonomous cortisol secretion.

  2021cited by this paper
• Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis

  2021cited by this paper
• Local steroid activation is a critical mediator of the anti-inflammatory actions of therapeutic glucocorticoids

  2020cited by this paper
• Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects

  2019cited by this paper
• 11β-HSD1 plays a critical role in trabecular bone loss associated with systemic glucocorticoid therapy

  2019cited by this paper
• Topical 11&bgr;-Hydroxysteroid Dehydrogenase Type 1 Inhibition Corrects Cutaneous Features of Systemic Glucocorticoid Excess in Female Mice

  2018cited by this paper
• 11β-hydroxysteroid dehydrogenase-1 deficiency alters brain energy metabolism in acute systemic inflammation

  2017cited by this paper
• Immune regulation by glucocorticoids

  2017cited by this paper
• The OMERACT Core Domain Set for Outcome Measures for Clinical Trials in Polymyalgia Rheumatica

  2017cited by this paper
• Glucocorticoids and 11β-HSD1 are major regulators of intramyocellular protein metabolism

  2016cited by this paper
• 11β-HSD1 is the major regulator of the tissue-specific effects of circulating glucocorticoid excess

  2014cited by this paper
• Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT‐384 in Healthy Volunteers and Elderly Adults

  2013cited by this paper
• Prednisone affects inflammation, glucose tolerance, and bone turnover within hours of treatment in healthy individuals.

  2012cited by this paper
• 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative

  2012cited by this paper
• Glycyrrhizin could reduce ocular hypertension induced by triamcinolone acetonide in rabbits

  2011cited by this paper
• 11β-Hydroxysteroid Dehydrogenase Type 1, But Not Type 2, Deficiency Worsens Acute Inflammation and Experimental Arthritis in Mice

  2011cited by this paper
• Systematic review on the effect of glucocorticoid use on procoagulant, anti‐coagulant and fibrinolytic factors

  2010cited by this paper
• Improved heart function follows enhanced inflammatory cell recruitment and angiogenesis in 11betaHSD1-deficient mice post-MI.

  2010cited by this paper
• A case of cortisol producing adrenal adenoma without phenotype of Cushing's syndrome due to impaired 11beta-hydroxysteroid dehydrogenase 1 activity.

  2008cited by this paper
• The expression of 11 beta-hydroxysteroid dehydrogenase type I by lymphocytes provides a novel means for intracrine regulation of glucocorticoid activities.

  2005cited by this paper
• The Expression of 11β-Hydroxysteroid Dehydrogenase Type I by Lymphocytes Provides a Novel Means for Intracrine Regulation of Glucocorticoid Activities1

  2005cited by this paper
• Effects of short-term glucocorticoids on cardiovascular biomarkers.

  2005cited by this paper
• The contribution of visceral adipose tissue to splanchnic cortisol production in healthy humans.

  2005cited by this paper
• Expression of 11β-hydroxysteroid dehydrogenase type 1 permits regulation of glucocorticoid bioavailability by human dendritic cells

  2005cited by this paper
• Splanchnic cortisol production occurs in humans: evidence for conversion of cortisone to cortisol via the 11-beta hydroxysteroid dehydrogenase (11beta-hsd) type 1 pathway.

  2004cited by this paper
• 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response.

  2004cited by this paper
• Absence of Cushingoid phenotype in a patient with Cushing's disease due to defective cortisone to cortisol conversion.

  2002cited by this paper
• Establishment of the relative antiinflammatory potency of deflazacort and prednisone in polymyalgia rheumatica

  1987cited by this paper
• Measurement of patient outcome in arthritis.

  1980cited by this paper

• No citing papers are available for this paper.